Insider Selling: Centessa Pharmaceuticals (NASDAQ:CNTA) Insider Sells $3,150,761.25 in Stock

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) insider Karen Anderson sold 120,029 shares of the company’s stock in a transaction that occurred on Friday, March 13th. The stock was sold at an average price of $26.25, for a total transaction of $3,150,761.25. Following the completion of the transaction, the insider owned 62,085 shares in the company, valued at approximately $1,629,731.25. This trade represents a 65.91% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Centessa Pharmaceuticals Trading Down 3.3%

Shares of Centessa Pharmaceuticals stock opened at $26.33 on Monday. The company has a debt-to-equity ratio of 0.36, a current ratio of 10.56 and a quick ratio of 10.57. Centessa Pharmaceuticals PLC Sponsored ADR has a 1 year low of $9.60 and a 1 year high of $30.58. The firm has a market cap of $3.85 billion, a PE ratio of -14.39 and a beta of 1.54. The company has a 50 day simple moving average of $24.69 and a two-hundred day simple moving average of $24.34.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on CNTA. B. Riley Financial upped their target price on shares of Centessa Pharmaceuticals from $33.00 to $42.00 and gave the stock a “buy” rating in a research report on Monday, December 1st. TD Cowen restated a “buy” rating on shares of Centessa Pharmaceuticals in a research report on Wednesday, January 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research note on Wednesday, January 21st. Guggenheim upped their price objective on Centessa Pharmaceuticals from $28.00 to $43.00 and gave the stock a “buy” rating in a report on Tuesday, November 18th. Finally, Truist Financial raised their price objective on Centessa Pharmaceuticals from $33.00 to $38.00 and gave the company a “buy” rating in a report on Thursday, January 29th. Two research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $39.80.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Large investors have recently added to or reduced their stakes in the business. TD Waterhouse Canada Inc. purchased a new stake in Centessa Pharmaceuticals during the fourth quarter valued at about $25,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Centessa Pharmaceuticals in the fourth quarter worth about $36,000. T. Rowe Price Investment Management Inc. increased its holdings in shares of Centessa Pharmaceuticals by 7,580.0% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,536 shares of the company’s stock worth $39,000 after buying an additional 1,516 shares during the period. Wells Fargo & Company MN lifted its stake in shares of Centessa Pharmaceuticals by 42.4% in the 4th quarter. Wells Fargo & Company MN now owns 3,387 shares of the company’s stock valued at $85,000 after acquiring an additional 1,008 shares during the last quarter. Finally, Knott David M Jr purchased a new stake in Centessa Pharmaceuticals during the 4th quarter valued at about $100,000. Hedge funds and other institutional investors own 82.01% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.